6 May 2025

A new experimental drug improves motor function and prolongs life in an ALS model.

The MP-010 molecule, developed by Miramoon Pharma, acts on ryanodine receptors, opening a new therapeutic avenue for treating ALS, according to a study led by researchers from CIBERNED and several research institutes, including the IIS Aragón.